Qureshi Adnan I, Knape Charlene, Maroney John, Suri M Fareed K, Hopkins L Nelson
Department of Neurosurgery, Toshiba Stroke Research Center, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA.
J Neurosurg. 2003 Aug;99(2):264-70. doi: 10.3171/jns.2003.99.2.0264.
Carotid angioplasty with stent placement has been proposed as an alternative method for revascularization of carotid artery (CA) stenosis. A novel stent with a coiled sheet design (NexStent; EndoTex Interventional Systems, Inc., Cupertino, CA) has been introduced because it provides improved flexibility over conventional tubular designs during navigation through tortuous arterial segments. The authors report the results of a multicenter study in which they evaluated the safety, feasibility, and effectiveness of this stent in the treatment of CA stenosis.
Enrollment was limited to patients with 70% or more symptomatic or asymptomatic stenosis of the internal CA. The primary end point was a technically successful implantation procedure (delivery of the stent to the target siteand retrieval of the delivery device) resulting in less than 30% residual stenosis on angiograms obtained immediately postprocedure and no death or ipsilateral stroke immediately after or within 30 days following the procedure. The secondary effectiveness end point was prevention of an ipsilateral stroke within 31 days to 1 year postprocedure. The tertiary effectiveness end point was less than 70% residual stenosis demonstrated on CA Doppler ultrasonography performed at 6 and 12 months. Forty-four patients (mean age 71 years, range 51-89 years; 30 patients were men and 18 [41%] had symptomatic stenotic lesions) were treated using 45 NexStents (two stents were placed in one patient). Residual stenosis on postprocedure angiograms was less than 30% in all patients. The 1-month primary end point was achieved in 41 patients (93%). The three major adverse events that occurred within 30 days were one death related to congestive heart failure and two ipsilateral strokes, one of which resulted in death. No ipsilateral stroke occurred between 1 and 12 months postprocedure among 35 patients who completed the follow-up evaluation. Asymptomatic recurrent stenosis was identified in one patient at 6 months postprocedure, requiring the performance of repeated angioplasty.
Placement of the NexStent was feasible and resulted in the effective treatment of patients with CA stenosis, with promising long-term results.
颈动脉血管成形术加支架置入已被提议作为颈动脉(CA)狭窄血运重建的替代方法。一种具有盘绕片设计的新型支架(NexStent;EndoTex介入系统公司,加利福尼亚州库比蒂诺)已被引入,因为在通过迂曲动脉段导航时,它比传统管状设计具有更好的柔韧性。作者报告了一项多中心研究的结果,在该研究中他们评估了这种支架治疗CA狭窄的安全性、可行性和有效性。
入选患者限于颈内动脉有70%或以上有症状或无症状狭窄的患者。主要终点是技术上成功的植入手术(将支架输送到目标部位并取回输送装置),术后立即获得的血管造影显示残余狭窄小于30%,且术后即刻或30天内无死亡或同侧卒中。次要有效性终点是术后31天至1年内预防同侧卒中。三级有效性终点是术后6个月和12个月进行的CA多普勒超声检查显示残余狭窄小于70%。44例患者(平均年龄71岁,范围51 - 89岁;30例为男性,18例[41%]有症状性狭窄病变)使用45个NexStent进行治疗(1例患者置入了2个支架)。所有患者术后血管造影的残余狭窄均小于30%。41例患者(93%)达到了1个月的主要终点。30天内发生的3例主要不良事件为1例与充血性心力衰竭相关的死亡和2例同侧卒中,其中1例导致死亡。在完成随访评估的35例患者中,术后1至12个月未发生同侧卒中。1例患者在术后6个月发现无症状性再狭窄,需要再次进行血管成形术。
NexStent的置入是可行的,能有效治疗CA狭窄患者,长期结果令人满意。